SCHEMBL31709751

SCHEMBL31709751

COC(=O)c1ccc(-n2ccc([N+](=O)[O-])n2)c(F)c1C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.38
PLAU P00749 3/20 0.38
KLKB1 P03952 3/20 0.38
ELANE P08246 3/20 0.38
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 5/20 0.36
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35
WDR5 P61964 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
GAA P10253 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31710309 0.81 KMT2A (0.38) KDM4EL3MBTL1KMT2AALDH1A1POLB
SCHEMBL31710090 0.78 CYP1A2 (0.55) F2PLAUKLKB1ELANEKDM4E
SCHEMBL31709902 0.76 KMT2A (0.44) F2PLAUKLKB1ELANEKDM4E
SCHEMBL17184346 0.74 SMN1; SMN2 (0.47) KDM4EL3MBTL1KMT2AALDH1A1MEN1
SCHEMBL31710511 0.71 KMT2A (0.49) F2PLAUKLKB1ELANEKDM4E
SCHEMBL25251210 0.69 HTT (0.52) F2PLAUKLKB1ELANEKDM4E
SCHEMBL31710502 0.68 GRM6 (0.32)
SCHEMBL31316911 0.68 TP53 (0.54) F2PLAUKLKB1ELANEL3MBTL1
SCHEMBL31316808 0.68 MAPK1 (0.48) F2PLAUKLKB1ELANEKDM4E
SCHEMBL543239 0.67 SMN1; SMN2 (0.42) KDM4EL3MBTL1KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224599-A1 PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-10-30 WO disclosed
US-20250326741-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326741-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF GIPR, GLP1R, GPR119 F2 1767/4885PLAU 1505/4885KLKB1 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.